Description: Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. It is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company markets its oral care technology into the Canadian pet specialty market under the bluestem brand. It has over 100 pet specialty stores in Canada, which are engaged in selling the bluestem oral health products. It has various formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial formulations for both the veterinary and human markets. It is focused on the development of oral care spray formulation and a water additive powder formulation.
Home Page: kanebiotech.com
KNE Technical Analysis
290-100 Innovation Drive
Winnipeg,
MB
R3T 6G2
Canada
Phone:
204 453 1301
Officers
| Name | Title |
|---|---|
| Mr. Marc Edwards | Pres, CEO & Director |
| Mr. Ray Dupuis | Chief Financial Officer |
| Mr. Kevin Cole | Pres & CEO of STEM Animal Health Inc |
| Dr. Gregory S. Schultz Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board |
| Lorne Gorber | Investor Relations |
| Ms. Lori Christofalos | VP of Quality & Compliance |
| Ms. Wendy Nachtigall | Director of Marketing |
| Nicole Sendey | Investor Relations Adviser |
| Mr. Mark Ahrens-Townsend | Advisor |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 104.3821 |
| Price-to-Sales TTM: | 4.4426 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |